Sophia Genetics reported Q2 revenue grew 27% year over year, driven by U.S. customer expansion and liquid biopsy sales, and announced a companion diagnostics collaboration with AstraZeneca. The partnership covers development, validation, and commercialization of two companion diagnostics—one for solid tumors and one for hematological cancers. Sophia said the AstraZeneca agreement leverages its global network and decentralized model, with commercial impact expected to begin next year. The company also expanded its precision medicine footprint through a separate collaboration with Memorial Sloan Kettering Cancer Center aimed at developing and launching new applications and multimodal clinical tools. Sophia raised full-year revenue guidance to between $94 million and $96 million and increased its AI-related investment plans, framing the CDx deal as an accelerator toward profitability.